These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9871603)

  • 21. Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo.
    Guth BD; Seewaldt-Becker E; Himmelsbach F; Weisenberger H; Müller TH
    J Cardiovasc Pharmacol; 1997 Aug; 30(2):261-72. PubMed ID: 9269956
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Three-dimensional quantitative structure-activity relationship analyses of RGD mimetics as fibrinogen receptor antagonists.
    Miyashita M; Akamatsu M; Hayashi Y; Ueno T
    Bioorg Med Chem Lett; 2000 May; 10(9):859-63. PubMed ID: 10853647
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preparation and biological activity of novel tricyclic GPIIb/IIIa antagonists.
    Robarge KD; Dina MS; Somers TC; Lee A; Rawson TE; Olivero AG; Tischler MH; Webb RR; Weese KJ; Aliagas I; Blackburn BK
    Bioorg Med Chem; 1998 Dec; 6(12):2345-81. PubMed ID: 9925295
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa (alphaIIb/beta3) receptor-directed platelet inhibition.
    Li YF; Spencer FA; Becker RC
    Am Heart J; 2001 Aug; 142(2):204-10. PubMed ID: 11479455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fluorinated dual antithrombotic compounds based on 1,4-benzoxazine scaffold.
    Ilić M; Kikelj D; Ilaš J
    Eur J Med Chem; 2012 Apr; 50():255-63. PubMed ID: 22365562
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glycoprotein IIb/IIIa inhibitors increase COAT-platelet production in vitro.
    Hamilton SF; Miller MW; Thompson CA; Dale GL
    J Lab Clin Med; 2004 May; 143(5):320-6. PubMed ID: 15122176
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-peptide glycoprotein IIb/IIIa antagonists. 11. Design and in vivo evaluation of 3,4-dihydro-1 (1H)-isoquinolinone-based antagonists and ethyl ester prodrugs.
    Hutchinson JH; Cook JJ; Brashear KM; Breslin MJ; Glass JD; Gould RJ; Halczenko W; Holahan MA; Lynch RJ; Sitko GR; Stranieri MT; Hartman GD
    J Med Chem; 1996 Nov; 39(23):4583-91. PubMed ID: 8917647
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ring constrained analogues of beta-alanine-containing GPIIb/IIIa receptor antagonists.
    Sielecki TM; Wityak J; Liu J; Mousa SA; Thoolen M; Wexler RR; Olson RE
    Bioorg Med Chem Lett; 2000 Mar; 10(5):449-52. PubMed ID: 10743945
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel non-peptide GPIIb/IIIa antagonists: synthesis and biological activities of 2-[4-[2-(4-amidinobenzoylamino)-2-(substituted)acetyl]-3-(2-methoxy-2-oxoethyl)-2-oxopiperazinyl] acetic acids.
    Kitamura S; Fukushi H; Miyawaki T; Kawamura M; Terashita Z; Sugihara H; Naka T
    Chem Pharm Bull (Tokyo); 2001 Mar; 49(3):258-67. PubMed ID: 11253914
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular modelling and conformational analysis of novel glycoprotein (Gp) IIb/IIIa antagonists. Molecular orbital calculation and the condensed heterocyclic derivatives.
    Ono S; Inoue Y; Yoshida T; Kosaka K; Maeda K; Imada T; Fukaya C; Nakamura N
    Eur J Med Chem; 2000 Jun; 35(6):577-92. PubMed ID: 10906410
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glycoprotein IIb/IIIa inhibition enhances platelet nitric oxide release.
    Chakrabarti S; Clutton P; Varghese S; Cox D; Mascelli MA; Freedman JE
    Thromb Res; 2004; 113(3-4):225-33. PubMed ID: 15140587
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis, and structure-activity relationships of potent GPIIb/IIIa antagonists: discovery of FK419.
    Yamanaka T; Ohkubo M; Kuroda S; Nakamura H; Takahashi F; Aoki T; Mihara K; Seki J; Kato M
    Bioorg Med Chem; 2005 Jul; 13(13):4343-52. PubMed ID: 15927840
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Profound and sustained inhibition of platelet aggregation by Fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, Lefradafiban, in men.
    Müller TH; Weisenberger H; Brickl R; Narjes H; Himmelsbach F; Krause J
    Circulation; 1997 Aug; 96(4):1130-8. PubMed ID: 9286940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade.
    Coller BS; Lang D; Scudder LE
    Circulation; 1997 Feb; 95(4):860-7. PubMed ID: 9054743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Conformational preferences in a benzodiazepine series of potent nonpeptide fibrinogen receptor antagonists.
    Keenan RM; Callahan JF; Samanen JM; Bondinell WE; Calvo RR; Chen L; DeBrosse C; Eggleston DS; Haltiwanger RC; Hwang SM; Jakas DR; Ku TW; Miller WH; Newlander KA; Nichols A; Parker MF; Southhall LS; Uzinskas I; Vasko-Moser JA; Venslavsky JW; Wong AS; Huffman WF
    J Med Chem; 1999 Feb; 42(4):545-59. PubMed ID: 10052962
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Augmentation of inhibitory effects of glycoprotein IIb-IIIa antagonists in patients with diabetes.
    Keating FK; Whitaker DA; Sobel BE; Schneider DJ
    Thromb Res; 2004; 113(1):27-34. PubMed ID: 15081562
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
    Rossi F; Rossi E; Pareti FI; Colli S; Tremoli E; Gallo L
    Haematologica; 2001 Feb; 86(2):192-8. PubMed ID: 11224490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa.
    Schneider DJ; Taatjes DJ; Sobel BE
    Cardiovasc Res; 2000 Jan; 45(2):437-46. PubMed ID: 10728364
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fibrinogen receptor (GPIIb-IIIa) antagonists derived from 5,6-bicyclic templates. Amidinoindoles, amidinoindazoles, and amidinobenzofurans containing the N-alpha-sulfonamide carboxylic acid function as potent platelet aggregation inhibitors.
    Su T; Naughton MA; Smyth MS; Rose JW; Arfsten AE; McCowan JR; Jakubowski JA; Wyss VL; Ruterbories KJ; Sall DJ; Scarborough RM
    J Med Chem; 1997 Dec; 40(26):4308-18. PubMed ID: 9435900
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential antiplatelet effects of various glycoprotein IIb-IIIa antagonists.
    Dickfeld T; Ruf A; Pogatsa-Murray G; Müller I; Engelmann B; Taubitz W; Fischer J; Meier O; Gawaz M
    Thromb Res; 2001 Jan; 101(2):53-64. PubMed ID: 11342206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.